Product Information
ENOXAPARIN 300 MG/3 ML VIAL is a generic product labeled by Amphastar Pharmaceuticals, Inc., priced at $9.8724 per ML under NDC 00548560800. Its NADAC has been published 287 times since Jan 8, 2020.
FDA first approved this application on Mar 14, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/3mL
Manufacturer
Amphastar Pharmaceuticals, Inc.NDC
00548560800
Classification
Generic
Dosage Form
INJECTION
Route
INTRAVENOUS; SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
ENOXAPARIN SODIUMApproval Type
Generic (ANDA)
FDA Application
ANDA208600FDA Approved
3/14/2019
TE Code
AB
On Market Since
11/11/2019
Pharmacological Classes
Price Statistics
The NADAC for ENOXAPARIN 300 MG/3 ML VIAL has been published 287 times since Jan 8, 2020, and over the history we have for it it has declined 57.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.8724 per ML |
|---|---|
| All-time high | $23.2005 (Apr 15, 2020) |
| All-time low | $9.8724 (Sep 23, 2026) |
| 52-week high | $11.6405 |
| 52-week low | $9.8724 |
| Median price | $12.5053 |
| Average price | $13.0043 |
| Largest weekly change | -32.2% (Apr 22, 2020) |
| Weeks tracked | 287 |
| Tracking since | Jan 8, 2020 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Amphastar Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
enoxaparin sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Low Molecular Weight Heparin class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ENOXAPARIN 300 MG/3 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for ENOXAPARIN 300 MG/3 ML VIAL, manufactured by Amphastar Pharmaceuticals, Inc., is $9.8724 per ML (NDC 00548560800), effective Sep 30, 2026.
How has the price of ENOXAPARIN 300 MG/3 ML VIAL changed over time?
Over the history we have for it, the NADAC for ENOXAPARIN 300 MG/3 ML VIAL has declined 57.4%. It has been tracked across 287 weekly CMS publications since Jan 8, 2020.
What are the highest and lowest recorded NADAC prices for ENOXAPARIN 300 MG/3 ML VIAL?
Since Jan 8, 2020, the NADAC for ENOXAPARIN 300 MG/3 ML VIAL has ranged from a low of $9.8724 (Sep 23, 2026) to a high of $23.2005 (Apr 15, 2020), with a median of $12.5053 per ML.
Are there cheaper alternatives to ENOXAPARIN 300 MG/3 ML VIAL?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ENOXAPARIN 300 MG/3 ML VIAL in a comparable dosage form, but none are currently priced below it.
Who manufactures ENOXAPARIN 300 MG/3 ML VIAL?
ENOXAPARIN 300 MG/3 ML VIAL (NDC 00548560800) is labeled by Amphastar Pharmaceuticals, Inc., and CMS classifies it as a generic product.